Human pan-cancer analysis of the predictive biomarker for the CDKN3
- PMID: 38720365
- PMCID: PMC11077798
- DOI: 10.1186/s40001-024-01869-6
Human pan-cancer analysis of the predictive biomarker for the CDKN3
Abstract
Background: Cell cycle protein-dependent kinase inhibitor protein 3 (CDKN3), as a member of the protein kinase family, has been demonstrated to exhibit oncogenic properties in several tumors. However, there are no pan-carcinogenic analyses for CDKN3.
Methods: Using bioinformatics tools such as The Cancer Genome Atlas (TCGA) and the UCSC Xena database, a comprehensive pan-cancer analysis of CDKN3 was conducted. The inverstigation encompassed the examination of CDKN3 function actoss 33 different kinds of tumors, as well as the exploration of gene expressions, survival prognosis status, clinical significance, DNA methylation, immune infiltration, and associated signal pathways.
Results: CDKN3 was significantly upregulated in most of tumors and correlated with overall survival (OS) of patients. Methylation levels of CDKN3 differed significantly between tumors and normal tissues. In addition, infiltration of CD4 + T cells, cancer-associated fibroblasts, macrophages, and endothelial cells were associated with CDKN3 expression in various tumors. Mechanistically, CDKN3 was associated with P53, PI3K-AKT, cell cycle checkpoints, mitotic spindle checkpoint, and chromosome maintenance.
Conclusion: Our pan-cancer analysis conducted in the study provides a comprehensive understanding of the involvement of CDKN3 gene in tumorigenesis. The findings suggest that targeting CDKN3 may potentially lead to novel therapeutic strategies for the treatment of tumors.
© 2024. The Author(s).
Conflict of interest statement
All the authors declare no conficts of interest.
Figures
![Fig. 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11077798/bin/40001_2024_1869_Fig1_HTML.gif)
![Fig. 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11077798/bin/40001_2024_1869_Fig2_HTML.gif)
![Fig. 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11077798/bin/40001_2024_1869_Fig3_HTML.gif)
![Fig. 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11077798/bin/40001_2024_1869_Fig4_HTML.gif)
![Fig. 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11077798/bin/40001_2024_1869_Fig5_HTML.gif)
![Fig. 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11077798/bin/40001_2024_1869_Fig6_HTML.gif)
![Fig. 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11077798/bin/40001_2024_1869_Fig7_HTML.gif)
![Fig. 8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/11077798/bin/40001_2024_1869_Fig8_HTML.gif)
Similar articles
-
Cyclin dependent kinase inhibitor 3 (CDKN3) upregulation is associated with unfavorable prognosis in clear cell renal cell carcinoma and shapes tumor immune microenvironment: A bioinformatics analysis.Medicine (Baltimore). 2023 Sep 8;102(36):e35004. doi: 10.1097/MD.0000000000035004. Medicine (Baltimore). 2023. PMID: 37682177 Free PMC article.
-
Cyclin-Dependent Kinase Inhibitor 3 Promotes Cancer Cell Proliferation and Tumorigenesis in Nasopharyngeal Carcinoma by Targeting p27.Oncol Res. 2017 Nov 2;25(9):1431-1440. doi: 10.3727/096504017X14835311718295. Epub 2017 Jan 20. Oncol Res. 2017. PMID: 28109073 Free PMC article.
-
CDKN3 mRNA as a Biomarker for Survival and Therapeutic Target in Cervical Cancer.PLoS One. 2015 Sep 15;10(9):e0137397. doi: 10.1371/journal.pone.0137397. eCollection 2015. PLoS One. 2015. PMID: 26372210 Free PMC article.
-
Expression and alternative splicing of the cyclin-dependent kinase inhibitor-3 gene in human cancer.Int J Biochem Cell Biol. 2017 Oct;91(Pt B):98-101. doi: 10.1016/j.biocel.2017.05.013. Epub 2017 May 11. Int J Biochem Cell Biol. 2017. PMID: 28504190 Free PMC article. Review.
-
Targeting CDKN3 in cervical cancer.Expert Opin Ther Targets. 2014 Oct;18(10):1149-62. doi: 10.1517/14728222.2014.941808. Epub 2014 Aug 25. Expert Opin Ther Targets. 2014. PMID: 25152075 Review.
References
-
- Wang L, Sun L, Huang J, Jiang M. Cyclin-dependent kinase inhibitor 3 (CDKN3) novel cell cycle computational network between human non-malignancy associated hepatitis/cirrhosis and hepatocellular carcinoma (HCC) transformation. Cell Prolif. 2011;44:291–299. doi: 10.1111/j.1365-2184.2011.00752.x. - DOI - PMC - PubMed
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous